trending Market Intelligence /marketintelligence/en/news-insights/trending/Olr_CYg2rYEvW_aIXcm5-w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Alkermes-Biogen's MS therapy receives tentative approval from US FDA

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Alkermes-Biogen's MS therapy receives tentative approval from US FDA

Alkermes PLC and its partner Biogen Inc. received the U.S. Food and Drug Administration's tentative approval for Vumerity to treat multiple sclerosis.

MS is a chronic inflammatory disease in which nerve damage disrupts communication between the brain and body. In relapsing-remitting MS, patients experience flare-ups or relapses of the disease's symptoms. Between flare-ups, patients have periods of partial or complete recovery, called remission.

Vumerity, or diroximel fumarate, showed a lower risk of gastrointestinal distress in patients compared to Biogen's own previously approved therapy, Tecfidera, in a late-stage study dubbed Evolve-MS-2.

The FDA said final approval of the drug is subject to expiration of a period of patent protection. Alkermes said it believes this period relates to the term of a patent of the reference listed drug — Tecfidera — set to expire Oct. 20.

Dublin-based Alkermes licensed diroximel fumarate to Cambridge, Mass.-based Biogen in 2017, and agreed to maintain responsibility for regulatory interactions with the FDA.